TY - JOUR

T1 - Glukagonlignende peptid 1-receptoragonisten semaglutid

AU - Boje, Amalie Dyhrberg

AU - Juhl, Christian Rimer

AU - Torekov, Signe Sørensen

AU - Madsbad, Sten

PY - 2019

Y1 - 2019

N2 - Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

AB - Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Glucagon-Like Peptide-1 Receptor

KW - Glucagon-Like Peptides/therapeutic use

KW - Humans

KW - Hypoglycemic Agents/therapeutic use

M3 - Tidsskriftartikel

C2 - 31610830

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V03190155

ER -